Affymetrix Investor Settles Suit Over $1.3B Thermo Fisher Sale
An Affymetrix shareholder will settle proposed class claims alleging the biotech's $1.3 billion buyout by Thermo Fisher resulted from a curtailed sales process due to a conflict of interest with its...To view the full article, register now.
Already a subscriber? Click here to view full article